Semaglutide and Breastfeeding: What the Data Says

Mother nursing her infant at home

Semaglutide has not been proven safe during breastfeeding, and it has not been shown harmful either. The small amount of human data is reassuring: one study found no detectable drug in milk. But the data is thin, and the usual medical advice is to wait until you have finished breastfeeding before you start or restart it. If you are nursing and thinking about a GLP-1, the right first step is a conversation with your own clinician, who can weigh your baby’s age, your supply and your health needs.

This guide covers what the milk studies found, what the FDA label says, how Ozempic, Wegovy, Mounjaro and Zepbound compare, and what to do if you want to lose weight now.

Revive Meds
Get Clinical Guidance on GLP-1s
Revive Meds reviews each patient’s medical intake with a licensed clinician before prescribing GLP-1 therapy or other treatment.

Visit Revive Meds

TL;DR

  • Injectable semaglutide was not detected in the breast milk of eight women in a 2024 study, but the sample was tiny and the data does not cover exclusive breastfeeding or long-term infant outcomes.
  • Labels and medical groups generally advise against starting or continuing GLP-1 medicines while nursing. Oral semaglutide carries a specific warning because of an added ingredient, SNAC.
  • Tirzepatide (Mounjaro, Zepbound) looks similar in early data, but evidence is limited and caution is advised, especially with newborns and preterm infants.
  • Appetite suppression may cut your calorie intake and your milk supply, which is a real concern separate from the drug reaching the milk.
  • Tell any prescriber you are breastfeeding before treatment starts, and plan for a washout of several weeks if you want to stop before nursing.

Table of Contents

What the milk studies actually found

The study most often cited is a 2024 report from the InfantRisk Center. Researchers measured semaglutide in the milk of eight breastfeeding women who took subcutaneous semaglutide. Semaglutide was not detectable in their milk, and the authors concluded the levels were unlikely to be a clinical concern for infants.

A few details matter before you take that as a green light:

  • Small sample. Eight mothers cannot rule out rare or individual differences.
  • Mixed feeding. The mothers combined breast milk and formula, so there is no data on babies who are exclusively breastfed, according to the study’s own discussion.
  • Worst-case modeling. Even when the researchers modeled a worst case, the estimated relative infant dose came to roughly 1.26%, well under the 10% threshold commonly used as a comfort line in lactation pharmacology.
  • No long-term follow-up. Nobody has tracked infant growth, gut development or neurodevelopment over months of exposure.

Semaglutide is a large protein-like molecule, and it binds heavily to proteins in the blood. Both traits limit how much can cross into milk. If a baby does swallow some, stomach digestion probably breaks most of it down. That is the reasoning behind the reassuring early results. It is a reasonable theory with limited human confirmation, and clinicians stress that reassuring short-term data is not the same as proven safe for prolonged use.

What the FDA label says

For injectable semaglutide, the FDA-approved Wegovy label says there are no human data on whether the drug is present in breast milk or what it does to a nursing infant. Prescribers are directed to weigh the benefits of the medicine against the unknown risks, which is different from a flat ban. You can read it in the current Wegovy prescribing information.

The oral tablet is a different story. Oral semaglutide contains an absorption enhancer called salcaprozate sodium (SNAC). The label notes that SNAC has been found in milk and that infants clear it more slowly than adults, so breastfeeding is not recommended with the tablet. Injectable forms do not contain SNAC. A drug reference summary reaches the same split: only injectable forms should be used during breastfeeding, if at all.

A separate summary from a teratology information service says there is no available information on semaglutide in human milk, while an animal study suggests small amounts are expected to reach milk. Sources differ in tone because they were written at different times, and the newer human study has not changed every document yet.

What the FDA label says — overview diagram

Ozempic, Wegovy, Mounjaro and Zepbound: same question, same caution

Ozempic and Wegovy are both brand names for semaglutide injections. The active ingredient is identical, so the milk data applies to both. Ozempic is labeled for type 2 diabetes, and Wegovy for weight management and cardiovascular risk reduction. Rybelsus and the Wegovy tablet are the oral versions, and they carry the SNAC concern above.

Mounjaro and Zepbound are tirzepatide. Its lactation record is slightly different:

  • Lilly reports that in a single-dose study of 11 lactating women given 5 mg, tirzepatide was undetectable in most milk samples. The company still states that there are no data on effects on the breastfed infant or on milk production.
  • The NIH’s LactMed database says tirzepatide is usually undetectable in breast milk at subcutaneous doses up to 5 mg, and that infant absorption is unlikely because the drug is probably partly destroyed in the infant’s gut. It advises caution given limited data, particularly with newborns and preterm infants.

So on both drugs the early picture is encouraging, and on both the evidence base is small. If you want a side-by-side on how the two medicines differ for adults who are not nursing, our tirzepatide vs semaglutide comparison covers it.

The risk people overlook: your calories and your supply

Even if no drug reached the milk, GLP-1s do what they are designed to do: they reduce appetite. Clinicians worry about the indirect effect on the nursing pair, where a mother eats too little, her supply drops or the nutritional quality of her milk suffers, and the baby gets less than needed. Nursing already raises your energy needs, and many people on semaglutide report losing interest in food. Our own explainer on how GLP-1s change appetite shows how strong that effect can be.

If you are breastfeeding and under any medication that dampens appetite, watch for:

  • Fewer wet or dirty diapers in your baby, or slower weight gain at pediatric checks.
  • A noticeable drop in how much you pump or how long feeds last.
  • Fatigue, dizziness or nausea that makes it hard to eat and drink enough.

Call your pediatrician about changes in your baby and your own clinician about changes in you. Do not wait for the next scheduled visit.

The washout problem

Semaglutide has a half-life of about a week, so it stays in your system for weeks after the last dose. A review of GLP-1 use in pregnancy and lactation describes a washout period often cited as 5 to 8 weeks. That makes “just pause while nursing” less simple than it sounds. If you take a dose and later decide you want to stop breastfeeding exposure, the drug does not leave right away.

Semaglutide half-life and washout timing

The same timing logic shows up if you are planning another pregnancy. Our pages on stopping semaglutide before pregnancy and fertility after semaglutide explain why clinicians suggest stopping about two months before trying to conceive.

A note on compounded semaglutide

Most milk research was done with the branded products. Compounded semaglutide is made by a pharmacy to a prescription, and it has not gone through the same FDA review for safety and effectiveness. That gap matters more when the patient is nursing, because the lactation data comes from a specific commercial formulation. Whatever source you use, tell your prescriber and the pharmacist that you are breastfeeding so they can factor it in.

Our perspective

We run a telehealth practice built around clinician-supervised GLP-1 care, so we hear this question often: new mothers who are tired of feeling stuck and want to know if medical weight loss can start now.

Our honest answer is that the early milk data is encouraging, and it still does not justify rushing. Every patient goes through a full medical intake that a licensed clinician reviews before anything is prescribed. Breastfeeding status belongs on that intake, in plain words, along with your baby’s age and whether you nurse exclusively. Those details change the risk calculation. A mother of a six-month-old who nurses twice a day is in a very different place from one with a newborn who feeds eight times.

We also think the supply concern gets less attention than it should. Weight loss in the first months of nursing works best when it is gradual and protects your milk, and a medicine that suppresses appetite works against that. For many women, waiting until weaning, or until nursing is only occasional, gives a safer and calmer start.

What we can promise is clear clinical review and ongoing access to your provider. Unlimited provider messaging is included, so you can ask questions as your situation changes. If your clinician says wait, that is a good outcome of the process, not a failure of it.

— Amy

What to do instead while you are nursing

You do not have to do nothing. Evidence-based options that fit with lactation include:

  1. Ask your OB or primary care clinician for a postpartum check. Thyroid problems, anemia, sleep loss and postpartum depression can all cause fatigue and weight changes.
  2. Eat enough. Aim for balanced meals with protein, fiber and fluids, and avoid crash diets. A registered dietitian who works with lactating patients can set a calorie floor.
  3. Move gradually. Walking and strength work can usually be added a few weeks after delivery, with your clinician’s go-ahead.
  4. Protect sleep where you can. Short sleep raises hunger and makes steady habits harder.
  5. Set a realistic pace. Many clinicians consider about one pound per week reasonable for a nursing mother who is losing weight, though your own provider should set the number.

If you have type 2 diabetes and are nursing, do not stop or switch a prescribed medicine on your own. Your endocrinologist or primary care doctor can go over which diabetes drugs have the best lactation record.

When you can consider starting after breastfeeding

Guidance generally points to waiting until breastfeeding has ended before starting or restarting a GLP-1 for weight management, as the FDA label and clinical consensus frame it. In practice:

  • If you plan to wean in the next few months, ask your clinician whether to wait for a washout and a full wean before the first dose.
  • If you want to nurse for a year or longer, discuss whether lifestyle, nutrition support and non-GLP-1 options make sense for now.
  • Know what to expect later. Weight regained after stopping is common, so plan for maintenance. Our guide on what happens when you stop semaglutide covers it.

A useful side note: a systematic review of GLP-1 safety in preconception, pregnancy and lactation was published in 2026, which shows how active this research area is. Recommendations may soften as more mothers are studied, so check with your clinician at the time you decide, not just today.

When you are ready to start

Once you have weaned and your clinician agrees, we can help. Revive Meds offers semaglutide injections from $199 per month, prescribed only after a clinician reviews your medical intake, with no membership fees and free shipping. Our women’s semaglutide page explains how care works for women, and if you want a different molecule, tirzepatide is also available. You can also read how semaglutide dosing works for US patients before your first visit.

FAQ

Is Ozempic safe while breastfeeding?

Ozempic is semaglutide, so the same evidence applies. One small study found no detectable drug in milk, but the FDA label for semaglutide notes there are no human data and asks prescribers to weigh benefits against unknown risks. Ozempic is prescribed for type 2 diabetes, so talk with the clinician managing your diabetes before changing anything.

Is Wegovy safe while breastfeeding?

Injectable Wegovy has no proven safety record in nursing, and most medical guidance recommends waiting until you finish breastfeeding. The Wegovy tablet is worse suited because it contains SNAC, which the label says is not recommended during breastfeeding. Ask your prescriber before using either form.

Can Mounjaro or tirzepatide be used while nursing?

Early data show tirzepatide is usually undetectable in milk at single doses up to 5 mg. Lilly and LactMed both say that effects on infants and on milk production are not established, and LactMed advises caution, particularly with newborns and preterm babies. It is a decision to make with your clinician, not a self-start.

Can semaglutide lower my milk supply?

No study has proven that it does, but the concern is logical. These medicines reduce appetite, and eating too little can reduce supply. If you ever use one while nursing, track your intake, your baby’s diapers and weight gain, and report changes right away.

How long does semaglutide stay in my system?

Its half-life is about one week, so it takes weeks to clear. Reviews cite a washout of roughly 5 to 8 weeks. Your clinician can tell you what timing makes sense if you are planning to wean or conceive.

Sources